US-based Cannabis Science has announced that it “will release an inhalation medication for those suffering asthma/COPD for use in patient nebulizers.” According to the company, the product would be available “in states where marijuana is legal on a national basis.”
The announcement does not specify when or how such a release would occur but it asserts that over half of the US states have laws that would allow the company to conduct studies of cannabidiol/tetrahydrocannabinol for the treatment of asthma and COPD.
The company suggests that “This could also be seen as a mechanism to verify the effectiveness of CBD/THC on patients that use the medication as a bronchodilator” and cites a long list of published studies as evidence that this type of product may be a better bronchodilator for COPD patients than either albuterol or ipratropium.
Read the Cannabis Science press release.
